G M Otter
Overview
Explore the profile of G M Otter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
88
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Piper J, Ramamurthy B, Johnson C, Otter G, Sirotnak F
J Med Chem
. 1996 Jan;
39(2):614-8.
PMID: 8558535
10-Deaza modifications of classical antifolate analogues bearing the 1,4-disubstituted naphthalene ring in place of the 1,4-disubstituted benzene ring were prepared and tested for antitumor activity. Naphthalene analogues (9a-c, respectively) of...
2.
Chou T, Otter G, Sirotnak F
Cancer Chemother Pharmacol
. 1996 Jan;
37(3):222-8.
PMID: 8529281
A new dihydrofolate reductase inhibitor, edatrexate (EDX), and the microtubule polymerization promotor, taxol (TXL) or taxotere (TXT), each have significant therapeutic activity against human breast cancer in clinical trials. Since...
3.
Su T, Chou T, Kim J, Huang J, Ciszewska G, Ren W, et al.
J Med Chem
. 1995 Aug;
38(17):3226-35.
PMID: 7650675
A series of DNA-intercalating 9-anilinoacridines, namely 9-phenoxyacridines, 9-(phenylthio)acridines, and 9-(3',5'-disubstituted anilino)acridines, were synthesized as potential antitumor agents with inhibitory effects on DNA topoisomerase II. Unlike amsacrine (m-AMSA), these agents were...
4.
Otter G, Sirotnak F
Cancer Chemother Pharmacol
. 1994 Jan;
33(4):286-90.
PMID: 8281620
Studies are described in which a new folate analogue, edatrexate (EDX), in combination with the vinca alkaloids, vinblastine (VBL), navelbine (NVB) or vindesine (DVA) was evaluated against E0771 mammary adenocarcinoma,...
5.
Bunni M, Sirotnak F, Otter G, Priest D
Cancer Chemother Pharmacol
. 1994 Jan;
34(6):455-8.
PMID: 7923554
Leucovorin (LV or 5-CHOFH4) has had long-standing clinical use as a rescue agent from the systemic toxic effects of methotrexate (MTX). Because the mouse has been the animal model most...
6.
Piper J, Johnson C, Maddry J, Malik N, McGuire J, Otter G, et al.
J Med Chem
. 1993 Dec;
36(26):4161-71.
PMID: 8277497
Analogues of classical antifolates with the 4-aminobenzoyl group replaced by 4-amino-1-naphthoyl were synthesized for study after molecular modeling indicated ample spatial accommodation for the naphthalene ring and even larger groups...
7.
Dicker A, Waltham M, Volkenandt M, Schweitzer B, Otter G, Schmid F, et al.
Proc Natl Acad Sci U S A
. 1993 Dec;
90(24):11797-801.
PMID: 8265628
A series of methotrexate (MTX)-resistant L1210 leukemia murine ascites tumors were developed in vivo and analyzed for drug resistance. Three of 20 tumors studied expressed an altered dihydrofolate reductase (DHFR)...
8.
Sirotnak F, Otter G, Schmid F
Cancer Res
. 1993 Feb;
53(3):587-91.
PMID: 8425192
10-Ethyl-10-deazaaminopterin (EDX, edatrexate) exhibits therapeutic activity against methotrexate (MTX)-resistant tumors in animals and patients. In an effort to improve its efficacy among more chemoresistant tumors, studies were initiated in murine...
9.
Piper J, Johnson C, Maddry J, McGuire J, Otter G, Sirotnak F
Adv Exp Med Biol
. 1993 Jan;
338:435-9.
PMID: 8304153
No abstract available.
10.
Piper J, Johnson C, Otter G, Sirotnak F
J Med Chem
. 1992 Aug;
35(16):3002-6.
PMID: 1501226
Previous findings suggesting that 5,10-dialkyl-substituted derivatives of 5,10-dideazaaminopterin warranted study as potential antifolates prompted synthesis of 10-ethyl-5-methyl-5,10- dideazaaminopterin (12a). The key step in the synthetic route to 12a was Wittig...